Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms
- PMID: 32185618
- DOI: 10.1007/s11307-020-01487-8
Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms
Abstract
Purpose: Considerable progress has been made in the assessment and management of non-small cell lung cancer (NSCLC) patients based on mutation status in the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS). At the same time, NSCLC management through KRAS and EGFR mutation profiling faces challenges. In the present work, we aimed to evaluate a comprehensive radiomics framework that enabled prediction of EGFR and KRAS mutation status in NSCLC patients based on radiomic features from low-dose computed tomography (CT), contrast-enhanced diagnostic quality CT (CTD), and positron emission tomography (PET) imaging modalities and use of machine learning algorithms.
Methods: Our study involved NSCLC patients including 150 PET, low-dose CT, and CTD images. Radiomic features from original and preprocessed (including 64 bin discretizing, Laplacian-of-Gaussian (LOG), and Wavelet) images were extracted. Conventional clinically used standard uptake value (SUV) parameters and metabolic tumor volume (MTV) were also obtained from PET images. Highly correlated features were pre-eliminated, and false discovery rate (FDR) correction was performed with the resulting q-values reported for univariate analysis. Six feature selection methods and 12 classifiers were then used for multivariate prediction of gene mutation status (provided by polymerase chain reaction (PCR)) in patients. We performed 10-fold cross-validation for model tuning to improve robustness, and our developed models were assessed on an independent validation set with 68 patients (common in all three imaging modalities). The average area under the receiver operator characteristic curve (AUC) was utilized for performance evaluation.
Results: The best predictive power for conventional PET parameters was achieved by SUVpeak (AUC 0.69, p value = 0.0002) and MTV (AUC 0.55, p value = 0.0011) for EGFR and KRAS, respectively. Univariate analysis of extracted radiomics features improved AUC performance to 0.75 (q-value 0.003, Short-Run Emphasis feature of GLRLM from LOG preprocessed image of PET with sigma value 1.5) and 0.71 (q-value 0.00005, Large Dependence Low Gray-Level Emphasis feature of GLDM in LOG preprocessed image of CTD with sigma value 5) for EGFR and KRAS, respectively. Furthermore, multivariate machine learning-based AUC performances were significantly improved to 0.82 for EGFR (LOG preprocessed image of PET with sigma 3 with variance threshold (VT) feature selector and stochastic gradient descent (SGD) classifier (q-value = 4.86E-05) and 0.83 for KRAS (LOG preprocessed image of CT with sigma 3.5 with select model (SM) feature selector and SGD classifier (q-value = 2.81E-09).
Conclusion: Our work demonstrated that non-invasive and reliable radiomics analysis can be successfully used to predict EGFR and KRAS mutation status in NSCLC patients. We demonstrated that radiomic features extracted from different image-feature sets could be used for EGFR and KRAS mutation status prediction in NSCLC patients and showed improved predictive power relative to conventional image-derived metrics.
Keywords: EGFR; KRAS; Machine learning; NSCLC; PET/CT; Radiogenomics.
Similar articles
-
Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review.Br J Radiol. 2021 Jun 1;94(1122):20201272. doi: 10.1259/bjr.20201272. Epub 2021 May 12. Br J Radiol. 2021. PMID: 33882244 Free PMC article.
-
Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images.Comput Biol Med. 2022 Mar;142:105230. doi: 10.1016/j.compbiomed.2022.105230. Epub 2022 Jan 11. Comput Biol Med. 2022. PMID: 35051856
-
Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer.Int J Mol Sci. 2021 Aug 26;22(17):9254. doi: 10.3390/ijms22179254. Int J Mol Sci. 2021. PMID: 34502160 Free PMC article.
-
Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2058-65. doi: 10.1007/s00259-014-2833-4. Epub 2014 Jul 3. Eur J Nucl Med Mol Imaging. 2014. PMID: 24990403
-
Accuracy of machine learning in preoperative identification of genetic mutation status in lung cancer: A systematic review and meta-analysis.Radiother Oncol. 2024 Jul;196:110325. doi: 10.1016/j.radonc.2024.110325. Epub 2024 May 10. Radiother Oncol. 2024. PMID: 38734145
Cited by
-
COVID-19 prognostic modeling using CT radiomic features and machine learning algorithms: Analysis of a multi-institutional dataset of 14,339 patients.Comput Biol Med. 2022 Jun;145:105467. doi: 10.1016/j.compbiomed.2022.105467. Epub 2022 Mar 29. Comput Biol Med. 2022. PMID: 35378436 Free PMC article.
-
Radiomics Analysis on Computed Tomography Images for Prediction of Chemoradiation-induced Heart Failure in Breast Cancer by Machine Learning Models.J Med Signals Sens. 2025 May 1;15:14. doi: 10.4103/jmss.jmss_51_24. eCollection 2025. J Med Signals Sens. 2025. PMID: 40421235 Free PMC article.
-
A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma.Front Oncol. 2021 Mar 2;11:603882. doi: 10.3389/fonc.2021.603882. eCollection 2021. Front Oncol. 2021. PMID: 33738250 Free PMC article.
-
Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review.Br J Radiol. 2021 Jun 1;94(1122):20201272. doi: 10.1259/bjr.20201272. Epub 2021 May 12. Br J Radiol. 2021. PMID: 33882244 Free PMC article.
-
Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.Diagnostics (Basel). 2022 May 27;12(6):1329. doi: 10.3390/diagnostics12061329. Diagnostics (Basel). 2022. PMID: 35741138 Free PMC article. Review.
References
-
- Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA (2010) Personalized medicine in non–small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor–targeted therapy? J Clin Oncol 28:4769–4777 - PubMed
-
- Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L (2011) Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:707–715 - PubMed
-
- Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972 - PubMed
-
- Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900–5909 - PubMed
-
- Riely GJ, Marks J, Pao W (2009) KRAS mutations in non–small cell lung cancer. Ann Am Thorac Soc 6:201–205
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous